FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Use in Inflammatory Bowel Disease
Eli Lilly and Company has announced that the U.S. FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults. This approval marks a…
WuXi Biologics CEO Dr. Chris Chen: Ready for Rapid Expansion
WuXi Biologics, delivered a keynote address at the 43rd J.P. Morgan Healthcare Conference, providing an insightful look into the company’s latest achievements, strategies, and future outlook. His presentation highlighted WuXi…
UCB Highlights a Decade of Growth and Patient-Centered Innovation Strategy
UCB is A global biopharmaceutical leader committed to improving the lives of people living with severe diseases, highlighted its decade of growth and strategic priorities at the 43rd J.P. Morgan…
Walgreens Resources for the ‘Quad-demic’ Vaccines, Treatments, and Support
Walgreens Steps Up Amid the ‘Quad-Demic’: Vaccines, Testing, Treatments, and Support The term “tripledemic” gained traction not too long ago to describe the simultaneous surges of flu, COVID-19, and respiratory…
Incyte and Syndax Announce FDA Approval of Niktimvo\u2122 (Axatilimab) in 9 mg and 22 mg Vials
Incyte and Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The companies expect the product to…
WHO Launches $1.5B Health Emergency Appeal
Unprecedented challenges such as conflict, climate change, epidemics, and displacement are converging to create a severe global health crisis, leaving 305 million people in dire need of humanitarian assistance in…
Orion Nomination Committee’s 2025 AGM Proposals
The Nomination Committee of Orion Corporation has provided its recommendations to the company’s Board of Directors regarding proposals for the 2025 Annual General Meeting (AGM). These recommendations address both the…
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802 Pheno Therapeutics Limited, a leading biotechnology company focused on developing small molecule therapeutics for neurological diseases, has received Clinical Trial…
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses At the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG revealed significant advancements in its pharmaceutical growth strategy, announcing multiple…
First Participants Enrolled in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease
First Participants Enrolled in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease AskBio Inc., a leading gene therapy company and a subsidiary of Bayer AG, announced today that the…
MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available
MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical…
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma The National Medical Products Administration (NMPA) of China has granted approval for Sarclisa (isatuximab), an anti-CD38 monoclonal antibody, in combination…